4 completed, 1 withdrawn. 5 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Completed 4, Withdrawn 1 |
| Phase 2 | 2 | Completed 1, Withdrawn 1 |
Follow Castration Levels of Testosterone: new trials by email Literature Review of Castration Levels of Testosterone trials Research Report on Castration Levels of Testosterone
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Enzalutamide and Decitabine in Treating Patients With Metastatic Castration Resistant Prostate Cancer Decitabine, Enzalutamide - Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma | Phase 1 / Phase 2 | Withdrawn | Roswell Park Cancer Institute | 2021-04-15 | 2022-10-05 | |
| Enzalutamide With Venetoclax in Treating Patients With Metastatic Castration Resistant Prostate Cancer Enzalutamide, Venetoclax - Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma | Phase 1 | Completed | Roswell Park Cancer Institute | 10 | 2019-08-02 | 2023-10-16 |
| 177Lu-PSMA-617 and Pembrolizumab in Treating Patients With Metastatic Castration-Resistant Prostate Cancer Lutetium Lu 177-PSMA-617, Pembrolizumab - Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma | Phase 1 | Completed | University of California, San Francisco | 43 | 2019-05-10 | 2025-02-25 |
| Niclosamide and Enzalutamide in Treating Patients With Castration-Resistant, Metastatic Prostate Cancer Enzalutamide, Laboratory Biomarker Analysis, Niclosamide - Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma | Phase 1 | Completed | University of Washington | 5 | 2015-12-31 | 2018-04-18 |
| Cabazitaxel With or Without Carboplatin in Treating Patients With Previously Treated Metastatic Castration-Resistant Prostate Cancer Cabazitaxel, Carboplatin, Laboratory Biomarker Analysis - Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma | Phase 1 / Phase 2 | Completed | M.D. Anderson Cancer Center | 170 | 2012-07-11 | 2021-07-30 |
Prostatic Neoplasms (5) · Lymphadenopathy (1)
Genital Diseases (5) · Genital Diseases, Male (5) · Genital Neoplasms, Male (5) · Male Urogenital Diseases (5) · Neoplasms (5) · Neoplasms by Site (5) · Prostatic Diseases (5) · Urogenital Diseases (5) · Urogenital Neoplasms (5) · Hemic and Lymphatic Diseases (1) · Lymphatic Diseases (1)
enzalutamide (3) · Carboplatin (1) · Decitabine (1) · Injections (1) · Niclosamide (1) · Pluvicto (1) · XRP6258 (1) · cabazitaxel (1) · pembrolizumab (1) · venetoclax (1)
Roswell Park Cancer Institute (2) · M.D. Anderson Cancer Center (1) · University of California, San Francisco (1) · University of Washington (1)
United States (5)
Gurkamal Chatta (2) · Michael Schweizer (1) · Paul Corn (1) · Rahul Aggarwal, MD (1)
PMID 29856824, PMID 31515154, PMID 35405009, PMID 37922930, PMID 41315064
P30CA015704 (1), P30CA016672 (1), P50CA097186 (1), R01CA229354 (1)